Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: August 8, 2022

Investigational Drug Information for PBT-1033

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug PBT-1033?

PBT-1033 is an investigational drug.

There have been 7 clinical trials for PBT-1033. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1^st 2008.

The most common disease conditions in clinical trials are Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, and Endometrial Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, M.D. Anderson Cancer Center, and Mayo Clinic.

Summary for PBT-1033

US Patents	0
International Patents	0
US Patent Applications	155
WIPO Patent Applications	111
Japanese Patent Applications	48
Clinical Trial Progress	Phase 3 (2008-02-01)
Vendors	20

Recent Clinical Trials for PBT-1033

Title	Sponsor	Phase
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT	Jarrow Formulas Inc	Phase 1/Phase 2
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT	University of California, Irvine	Phase 1/Phase 2
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach	University of Maryland, Baltimore	Phase 2

See all PBT-1033 clinical trials

Clinical Trial Summary for PBT-1033

Top disease conditions for PBT-1033

Top clinical trial sponsors for PBT-1033

See all PBT-1033 clinical trials

US Patents for PBT-1033

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Merck

Medtronic

Moodys

Dow

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.